Eisai (TYO: 4523) and BioArctic (STO: BIOA-B) have announced the launch of Leqembi (lecanemab) in the Japanese market on December 20. The amyloid-beta (Aβ)-targeting drug received its second global approval in Japan earlier this year and has been incorporated into the National Health Insurance (NHI) system. Leqembi is indicated for the slowing of progression in mild cognitive impairment (MCI) and mild dementia attributed to Alzheimer’s disease (AD).
Leqembi is designed to target both soluble and insoluble forms of Aβ aggregates, including protofibrils and fibrils, aiming to reduce the accumulation of Aβ plaques in the brain. It is considered a groundbreaking disease-modifying treatment for AD.
Despite its potential benefits, Leqembi has faced scrutiny due to common adverse events such as cerebral hemorrhage, edema, and falls. The drug’s approval in Japan is subject to ongoing post-marketing surveillance through a special use results survey.- Flcube.com
